Biocept announces agreement with aegea biotechnologies

Biocept announces agreement with aegea biotechnologies to develop new, highly sensitive pcr-based covid-19 assay utilizing patented switch-blocker pcr technology.biocept inc - covid-19 pcr assay is based on core switch-blocker technology used in biocept's suite of ultra-sensitive oncology-focused assays.biocept inc - biocept has first option to negotiate a license agreement to any resulting new covid-19 pcr assay for commercialization.biocept inc - intellectual property underlying switch-blocker technology is jointly owned by biocept and aegea.
BIOC Ratings Summary
BIOC Quant Ranking